文献速递药物不良反应与药物警戒

通过培训与指导强化撒哈拉以南非洲药物警戒:GSK在马拉维的试点举措

Enhancing Pharmacovigilance in Sub-Saharan Africa Through Training and Mentoring: A GSK Pilot Initiative in Malawi.
PubMed 文献 · Drug Saf · 2020-01-01

在马拉维开展为期18个月的药物警戒培训与指导试点,培训61家医疗机构443名医护人员,不良事件报告数从22例增至228例,使马拉维加入WHO国际药物监测计划,但48小时内向国家药物警戒办公室传输报告的比例不足1%。

要点

  • 对医护人员定期开展药物警戒培训与指导可有效增加不良事件报告数量。
  • 报告表完整性好,98%包含报告者、事件、患者和产品等必填信息。
  • 报告及时传输至国家药物警戒中心的比例不足1%,需进一步改进。

核心结论

  • 对医护人员定期开展药物警戒培训与指导能有效增强马拉维的被动安全监测,但报告向国家药物警戒中心的传输仍需改进。

研究设计与样本

  • 在马拉维实施为期18个月的药物警戒培训与指导项目,与国家利益相关方合作,并与卫生部、GSK和PATH合作。
  • 为扩大免疫规划协调员和4名国家监管机构代表提供两天培训,并定期为医护人员提供简化药物警戒培训与指导。
  • 支持升级国家药物警戒系统,关键绩效指标包括不良事件报告数、报告表传输、报告完整性、严重不良事件报告及录入VigiFlow的及时性。

主要发现

  • 18个月内培训了61家医疗机构的443名医护人员。
  • 98%的不良事件报告表包含报告者、事件、患者和产品的必填信息,但不足1%在48小时内传输至国家药物警戒办公室。

临床怎么用

  • 在药物警戒体系薄弱地区,可对医护人员开展定期培训与现场指导以提升不良事件报告意识与报告数量。
  • 在推广培训的同时需优化报告传输流程,确保报告及时送达国家药物警戒中心。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Pharmacovigilance (PV) systems to monitor drug and vaccine safety are often inadequate in sub-Saharan Africa. In Malawi, a PV enhancement initiative was introduced to address major barriers to PV. OBJECTIVE: The objective of this initiative was to improve reporting of adverse events (AEs) by strengthening passive safety surveillance via PV training and mentoring of local PV stakeholders and healthcare providers (HCPs) at their own healthcare facilities (HCFs). METHODS: An 18-month PV training and mentoring programme was implemented in collaboration with national stakeholders, and in partnership with the Ministry of Health, GSK and PATH. Two-day training was provided to Expanded Programme on Immunisation coordinators, identified as responsible for AE reporting, and four National Regulatory Authority representatives. Abridged PV training and mentoring were provided regularly to HCPs. Support was given in upgrading the national PV system. Key performance indicators included the number of AEs reported, transmission of AE forms, completeness of reports, serious AEs reported and timeliness of recording into VigiFlow. RESULTS: In 18 months, 443 HCPs at 61 HCFs were trained. The number of reported AEs increased from 22 (January 2000 to October 2016) to 228 (November 2016 to May 2018), enabling Malawi to become a member of the World Health Organization Programme for International Drug Monitoring. Most (98%) AE report forms contained mandatory information on reporter, event, patient and product, but under 1% were transmitted to the national PV office within 48 h. CONCLUSION: Regular PV training and mentoring of HCPs were effective in enhancing passive safety surveillance in Malawi, but the transmission of reports to the national PV centre requires further improvement. When a medicine or vaccine is made available for use, healthcare organisations maintain regular surveillance to confirm that the medicinal product is safe and effective. The efficiency of this surveillance depends mainly on the healthcare system and medical practices in place in each country. An important element is an effective procedure for identifying and reporting any unwanted medical occurrences (adverse events) after taking a medicinal product. In countries where regular safety surveillance has not been maintained, it is important to train and mentor healthcare providers on the need to be aware of adverse events and the importance of adhering to safety reporting procedures. GSK and partners conducted a pilot project in Malawi with the aim of improving adverse event reporting by training and mentoring healthcare providers. Training sessions and continuous mentoring were conducted over 18 months, involving 443 healthcare providers at 61 healthcare facilities. There was a large increase in the number of adverse events reported: from 22 in the 16-year period before the project started to 228 during the 18-month project period. This project showed that the training and mentoring programme for healthcare providers was effective in increasing the number of adverse events reported. This enabled Malawi to join the World Health Organization’s international safety reporting scheme. Other countries facing similar challenges in safety surveillance systems could benefit from a similar approach.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Jusot V, Chimimba F, Dzabala N, et al. Enhancing Pharmacovigilance in Sub-Saharan Africa Through Training and Mentoring: A GSK Pilot Initiative in Malawi. Drug Saf. 2020. PMID: 32239447. doi:10.1007/s40264-020-00925-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。